Lovastatin Decreases the Expression of CD133 and Influences the Differentiation Potential of Human Embryonic Stem Cells
The lipophilic statin lovastatin decreases cholesterol synthesis and is a safe and effective treatment for the prevention of cardiovascular diseases. Growing evidence points at antitumor potential of lovastatin. Therefore, understanding the molecular mechanism of lovastatin function in different cel...
Saved in:
Main Authors: | Ade Kallas-Kivi, Annika Trei, Toivo Maimets |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2016-01-01
|
Series: | Stem Cells International |
Online Access: | http://dx.doi.org/10.1155/2016/1580701 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
SOX2 Is Regulated Differently from NANOG and OCT4 in Human Embryonic Stem Cells during Early Differentiation Initiated with Sodium Butyrate
by: Ade Kallas, et al.
Published: (2014-01-01) -
CD133 Antigen as a Potential Marker of Melanoma Stem Cells: In Vitro and In Vivo Studies
by: Tomasz Kloskowski, et al.
Published: (2020-01-01) -
Enhanced Expression of ABCB1 and Nrf2 in CD133-Positive Cancer Stem Cells Associates with Doxorubicin Resistance
by: Shinji Goto, et al.
Published: (2020-01-01) -
Combined prognostic value of the cancer stem cell markers CD47 and CD133 in esophageal squamous cell carcinoma
by: Jian‐Hua Wang, et al.
Published: (2019-03-01) -
Differences Between Lovastatin and Simvastatin Hydrolysis in Healthy Male and Female Volunteers: Gut Hydrolysis of Lovastatin is Twice that of Simvastatin
by: Tom B. Vree, et al.
Published: (2003-01-01)